MAY 28·finanznachrichten.de▲
Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen Bio Holdings (Nasdaq: TVGN) said it is continuing evaluations for strategic acquisitions, including a previously announced review of a contract research organization (CRO) and other opportunities for its healthcare platform. If consummated, the deals could support about $100 million in combined annual revenue, subject to due diligence, approvals, and closing conditions.
MAY 1·Stock Titan→
Tevogen Bio (NASDAQ: TVGN) adds governance, pay and related-party details
Tevogen Bio (TVGN) filed an amended annual report (10-K/A) for 2025 to include Part III information, which typically covers governance, executive compensation, and related-party transactions, without updating financial results. The amendment details the company's board structure, executive pay—including CEO Ryan Saadi's $10.4 million total compensation in 2025—and significant related-party financial arrangements with The Patel Family, LLP and its affiliates. It also specifies that CEO Ryan Saadi beneficially owns 59.45% of outstanding common stock, with all directors and executives collectively holding 67.91%.
